NewsRoom Articles - Page 77 of 154 - PsychedelicNewsWire (PNW)

FridayDec 03, 2021 2:30 pm

Former Texas Governor Promotes Research on Psychedelics for Veterans

Recently, the former governor of the state of Texas, Rick Perry, joined reform advocates and leading scientists at the Strength in Numbers gala. The event, which was centered on promoting studies on the therapeutic potential of substances such as MDMA and psilocybin for veterans, was hosted by Veterans Exploring Treatment Solutions. Earlier this year, Perry also advocated for a measure to study the medical use of psychedelic substances for veterans. During his remarks at the gala, Perry revealed that various experiences prompted him to look beyond the state for assistance, including one where he met a young military veteran with…

ThursdayDec 02, 2021 1:30 pm

Studies Find That Classic Psychedelics Aren’t Addictive

Pharmacologists at the University of Michigan Medical School tested psilocybin’s addiction potential in a study conducted in 2004. The study involved a cohort of rhesus monkeys, one-half of whom were injected with a dose of psilocybin, with the remainder hooked up to levers that injected them with a saline solution when pressed. In experiments similar to this, monkeys have often pressed levers that inject drugs, including MDMA, cocaine and heroin. For this study, however, the researchers observed that while some monkeys didn’t go for a second dose of the psychedelic compound, others administered the compound until they were intoxicated. In…

ThursdayDec 02, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

Report notes significant and swift advancements in company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period…

WednesdayDec 01, 2021 2:00 pm

Psychedelics May Alter How People View the Universe

Research on psychedelic substances has led to the discovery of the numerous benefits that these substances possess, which could be utilized in the treatment of various mental health conditions. A recent study has found that psychedelic substances can alter an individual’s beliefs on metaphysics. Metaphysics refers to a branch of philosophy that focuses on “being.” Some believe that every individual has metaphysical beliefs, whether they are conscious of those beliefs or not. Sharpening an individual’s understanding of metaphysics can be achieved with different techniques, including meditation. Having a near-death experience may also sharpen one’s understanding of the same. In an…

WednesdayDec 01, 2021 9:30 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Releases Q3 Update, Details JHU Five-Year Research Agreement

Mydecine’s recent Q3 update includes the company’s five-year research agreement with Johns Hopkins University School of Medicine, which will cover clinical research related to the therapeutic use of psychedelics Mydecine has also filed for various patents on proprietary compounds within the company’s IP portfolio In addition, an updated version of the company’s virtual health platform, Mindleap 2.0, was released in Q3, enhancing user experience, infrastructure improvement, and expansion of overall content Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), a company that focuses on bio- and digital technology that aims to transform the treatment of mental health and addiction…

TuesdayNov 30, 2021 3:00 pm

Psychedelics Firms Race to Shorten Therapeutic Trips’ Duration

Research on psychedelics has grown tremendously these past few years, as more about potential health benefits are discovered. For instance, substances such as psilocybin and MDMA have shown potential in the treatment of various conditions, including post-traumatic stress disorder and depression. Some research has shown that these substances may be even more effective than current treatments for these conditions, which can take weeks to begin working. The primary downside of these substances is the duration of psychedelic trips, which drug=development and biotech companies are working to make shorter. Normally, psychedelic trips range between 4 to 12 hours, depending on the…

MondayNov 29, 2021 2:00 pm

Study Finds That Use of Psychedelics Decreases Opioid Consumption

New research has found that the use of psychedelic substances such as DMT, mescaline, psilocybin and LSD is linked to a considerable decline in the consumption of opioids. For their study, the researchers analyzed data from cohorts comprised of individuals suffering from substance misuse disorders. These cohorts included more than 200 people who admitted to using psychedelic substances in the last six months while another 1,092 admitted to using opioids. The researchers found that using psychedelics was linked to a 55% decrease in the daily use of opioids. Their findings were published in the “Journal of International Drug Policy.” It…

MondayNov 29, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays

People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders There is no denying that food is a…

WednesdayNov 24, 2021 12:30 pm

Psilocybin Mushroom Measure May Make Pennsylvania New Psychedelic Research Hub

The state of Pennsylvania may become the new psychedelic research hub in the United States if a measure that was introduced in the state’s House of Representatives in October is approved. The measure, dubbed the Public Health Benefits of Psilocybin Act, will establish a framework for research on psilocybin to be conducted in order to determine its effectiveness as a treatment for various mental health conditions. Psilocybin is the active compound found in hallucinogenic mushrooms. The Health Committee will be voting on the initiative this coming week. The prime sponsor of the measure is Tracy Pennycuick, an army veteran. It…

TuesdayNov 23, 2021 12:00 pm

Study Finds Psilocybin Improves Neural, Cognitive Flexibility in Patients with Depression

A new study has found that psilocybin-assisted psychotherapy increases neural and cognitive flexibility in patients suffering from major depressive disorder. Psilocybin is the active compound found in hallucinogenic mushrooms. Research has found that the component has clinically substantial and long-lasting effects on mood and personality when used in conjunction with psychotherapy. The study was published in “Translational Psychiatry,” with researchers suggesting that psychedelic-induced increases in neural flexibility don’t always translate into cognitive improvements. The study’s authors were focused on assessing the effects of psilocybin on neural flexibility, which refers to variability in brain connectivity and activity, and cognitive flexibility, which…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000